Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirofiban for Early Treatment of Acute Ischemic Stroke (Multicenter RCT)
ChiCTR2600125063Phase 4Not yet recruiting
- Sponsor
- Army Medical University
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tirofiban in ischemic stroke (2 arms), sponsored by Army Medical University. Primary endpoints: 90-day mRS score 0-1, Incidence of symptomatic intracranial hemorrhage (SICH) within 48 hours and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
tirofiban
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2600125063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125063.